WuXi XDC Cayman Inc Logo
KYG9808A1058
A3ESJ3
L74.DU

WuXi XDC Cayman Inc

Loading quotes...

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • WuXi XDC Cayman: major shareholder places shares to raise capital – stock falls

    A major shareholder of WuXi XDC Cayman, STA Pharmaceutical Hongkong, placed 53.5 million shares at HK$73.23 each, apparently aiming to raise up to US$500 million. The news came with a substantial discount to the previous close and triggered a price drop of about 2.6% to HK$75.25. There was also profit-taking after WuXi’s strong half-year results. » More on de.investing.com


  • WuXi XDC posts first-half profit above RMB 1 billion — shares rise about 15%

    WuXi XDC reported H1 2026 revenue of RMB 3.7 billion (+37% year‑on‑year) and an adjusted net profit of over RMB 1 billion. Gross margin improved to 37% and order backlog rose to over USD 2 billion, including around USD 120 million of commercial orders. The stock climbed 14.8% to USD 80.15. Management reaffirmed the full-year guidance (consolidated currency‑adjusted revenue growth ~30%, standalone ≥35%) and highlighted effects from the ramp‑up of the new Singapore site and integration costs related to BioDLink. » More on de.investing.com


  • WuXi XDC rises almost 12% after strong H1 results

    WuXi XDC reported H1 2026 revenue of RMB 3.701 billion (+37% yoy) and an adjusted net profit attributable to shareholders of about RMB 1.027 billion (+37.4%). Gross margin improved to 37.0% and management cited the integration of BioDlink, the expansion of the global production network (including commercial production in Singapore) and the further development of its own technology platforms as drivers of structural growth. The stock then climbed roughly 12% to HK$78. » More on de.investing.com


  • Akari starts GMP production of AKTX-101 in partnership with WuXi XDC

    Akari Therapeutics has begun GMP-compliant manufacture of its lead ADC program AKTX-101 in an exclusive partnership with WuXi XDC to supply material for regulatory IND-enabling studies. AKTX-101 uses Akari’s PH1 payload, which modulates RNA splicing, and showed high efficacy versus traditional ADCs in preclinical studies. The company plans first-in-human phase 1 studies in about 12 months (end of 2026/early 2027, pending regulatory clearance), recently raised roughly $5 million in fresh capital, received a NASDAQ notice of non-compliance with the minimum bid price requirement, and appointed an interim CFO. » More on de.investing.com

Financials

In the last quarter, WuXi XDC Cayman Inc had revenue of €470.77M and net profit of €104.04M
(EUR) June 2026
YoY
Revenue 470.77M -
Gross profit 174.42M -
Net profit 104.04M -
EBITDA 152.19M -

Fundamentals

Metric Value
Market capitalization
€9.71B
Number of shares
1.27B
52-week high/low
€9.95 - €5.06
Dividends No
Beta
-0.78
P/E ratio
45.95
PEG ratio
2.09
P/B ratio
6.24
P/S ratio
10.29

Company profile

WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. The company was founded in 2013 and is headquartered in Wuxi, China. WuXi XDC Cayman Inc. operates as a subsidiary of WuXi Biologics (Cayman) Inc.

Name
WuXi XDC Cayman Inc
CEO
Jincai Li
Headquarters Wuxi, js
China
Website
Sector
Health Care
Industry
Life Sciences Tools & Services
IPO
06/18/2012
Employees 2,662

Ticker symbols

Exchange Symbol
Düsseldorf
L74.DU
Frankfurt
L74.F
München
L74.MU
🍪

Parqet  uses cookies. Learn more